XML 75 R65.htm IDEA: XBRL DOCUMENT
v3.25.1

Fair Value Measurements - Milestone Asset, Milestone Contingent Consideration and PRV Interest and Warrants (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended |  |
--- | --- | --- | --- | ---
Feb. 28, 2025 | Mar. 31, 2025 | Dec. 31, 2024 | Apr. 30, 2024
Fair Value Measurements |  |  |  |
Exarafenib milestone asset (Note 4) |  | $ 3,307 | $ 3,214 |
Exarafenib milestone contingent consideration (Note 4) |  | 3,307 | $ 3,214 |
Fair value of warrants |  | 605 |  |
Kinnate CVR holders | CVR Agreement |  |  |  |
Fair Value Measurements |  |  |  |
Exarafenib milestone asset (Note 4) |  | 3,300 |  |
Exarafenib milestone contingent consideration (Note 4) |  | 3,300 |  | $ 2,900
Increase in Exarafenib milestone asset |  | 100 |  |
Increase in Exarafenib milestone contingent consideration |  | $ 100 |  |
Castle Creek Biosciences, Inc | Royalty Financing Transaction |  |  |  |
Fair Value Measurements |  |  |  |
Rights entity acquired as a percentage of specified percentage | 6.70% |  |  |
Fair value of warrants | $ 600 |  |  |

X
- Definition Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value during the period from contingent consideration liability. + References No definition available. + Details
Name: | xoma_AssetAcquisitionContingentConsiderationLiabilityChangeInAmount
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value of investment in warrants, classified as noncurrent. + References No definition available. + Details
Name: | xoma_InvestmentWarrantsNoncurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase (decrease) in the value during the period of milestone assets. Amount represents initial fair value in accordance with ASC 825. + References No definition available. + Details
Name: | xoma_MilestoneAssetsIncreaseDecrease
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying amount as of the balance sheet date of milestone assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amount represents initial fair value in accordance with ASC 825. + References No definition available. + Details
Name: | xoma_MilestoneAssetsNoncurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The rights entity acquired as a percentage of specified percentage of net sales or as a specified percentage of proceeds from potential Priority Review Voucher. + References No definition available. + Details
Name: | xoma_RightsReceivablePercentageOnNetSalesAndProceeds
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_KinnateCvrHoldersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_ContingentValueRightsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_CastleCreekBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyFinancingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |